(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 39.86% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Transmedics Group's revenue in 2024 is $241,623,000.On average, 4 Wall Street analysts forecast TMDX's revenue for 2024 to be $12,007,175,278, with the lowest TMDX revenue forecast at $11,937,818,808, and the highest TMDX revenue forecast at $12,060,501,243. On average, 4 Wall Street analysts forecast TMDX's revenue for 2025 to be $15,592,544,905, with the lowest TMDX revenue forecast at $14,726,472,344, and the highest TMDX revenue forecast at $16,174,452,230.
In 2026, TMDX is forecast to generate $18,590,151,164 in revenue, with the lowest revenue forecast at $18,590,151,164 and the highest revenue forecast at $18,590,151,164.